Vaxart, Inc. (VXRT): Business Model Canvas [Jan-2025 Updated]

In the rapidly evolving landscape of vaccine technology, Vaxart, Inc. (VXRT) emerges as a groundbreaking innovator, revolutionizing the traditional vaccine delivery paradigm through its ingenious oral tablet platform. By challenging the conventional injectable vaccine model, Vaxart's unique approach promises to transform immunization strategies across global healthcare systems, offering a potentially game-changing solution that could simplify vaccine distribution, reduce administration complexities, and enhance accessibility for diverse populations worldwide.

Vaxart, Inc. (VXRT) - Business Model: Key Partnerships

Strategic Collaborations with Academic Research Institutions

Vaxart has established partnerships with the following academic research institutions:

Institution	Collaboration Focus	Year Established
University of Texas Medical Branch	COVID-19 vaccine development	2020
Baylor College of Medicine	Oral vaccine technology research	2019

Partnerships with Pharmaceutical Contract Development Organizations

Vaxart collaborates with contract development and manufacturing organizations (CDMOs):

• Emergent BioSolutions - Manufacturing support
• Catalent Pharma Solutions - Oral vaccine formulation
• WuXi Biologics - Preclinical and clinical development services

Licensing Agreements with Technology Transfer Partners

Partner	Technology Area	Agreement Terms
Intravacc Institute	Oral vaccine platform technology	Exclusive licensing agreement
Mount Sinai Innovation Partners	Vaccine antigen design	Non-exclusive technology transfer

Potential Government Health Agency Collaborations

Vaxart has engaged with the following government health agencies:

• National Institutes of Health (NIH) - COVID-19 vaccine research grant: $5.1 million in 2021
• Defense Advanced Research Projects Agency (DARPA) - Pandemic preparedness funding: $3.7 million in 2022

Total Partnership Funding Received in 2022-2023: $8.8 million

Vaxart, Inc. (VXRT) - Business Model: Key Activities

Oral Vaccine Platform Research and Development

As of Q4 2023, Vaxart has invested $12.3 million in oral vaccine platform research and development. The company maintains a dedicated research team of 37 scientists focused on oral vaccine technologies.

Research Focus Area	Annual Investment	Research Personnel
Oral Vaccine Platform	$12.3 million	37 scientists

Preclinical and Clinical Vaccine Trials

Vaxart has conducted 6 clinical trials as of 2024, with a total investment of $8.7 million in trial development and execution.

• COVID-19 vaccine trials: 3 completed
• Norovirus vaccine trials: 2 ongoing
• Influenza vaccine trials: 1 in preparation

Proprietary Tablet Vaccine Technology Innovation

The company has filed 14 patent applications related to tablet vaccine technology, with R&D expenditure of $5.6 million in this specific area.

Technology Category	Patent Applications	R&D Investment
Tablet Vaccine Platform	14 applications	$5.6 million

Immunology and Infectious Disease Vaccine Design

Vaxart has dedicated 45% of its research budget to immunology and infectious disease vaccine design, totaling approximately $7.2 million in 2024.

• Viral disease focus areas: COVID-19, Norovirus, Influenza
• Research team specialization: 22 immunologists

Intellectual Property Protection and Patent Filing

The company has allocated $3.1 million for intellectual property protection and maintains an active patent portfolio of 22 granted patents.

IP Category	Total Patents	Annual IP Protection Budget
Granted Patents	22	$3.1 million

Vaxart, Inc. (VXRT) - Business Model: Key Resources

Proprietary Oral Vaccine Delivery Platform

Vaxart's key resource includes a proprietary oral tablet vaccine technology platform. As of Q4 2023, the platform covers multiple vaccine development approaches.

Platform Characteristic	Specific Details
Patent Portfolio	17 issued patents as of December 2023
Technology Coverage	Viral vector and antigen delivery systems
Development Stage	Multiple preclinical and clinical-stage programs

Scientific Research and Development Team

Vaxart's R&D team comprises specialized biotechnology professionals.

• Total R&D Personnel: 48 employees as of December 2023
• PhD-level Scientists: 22 team members
• Vaccine Development Specialists: 16 researchers

Advanced Biotechnology Laboratory Facilities

Vaxart maintains specialized research infrastructure in San Francisco, California.

Facility Metric	Specification
Total Laboratory Space	8,500 square feet
BSL-2 Certified Areas	3 dedicated research zones
Annual R&D Investment	$24.3 million in 2023

Vaccine Design and Manufacturing Intellectual Property

Vaxart's intellectual property represents a critical resource for the company's vaccine development strategy.

• Total Patent Applications: 26
• Granted Patents: 17
• Patent Jurisdictions: United States, Europe, Asia

Clinical Trial Data and Research Archives

Comprehensive research documentation supports Vaxart's vaccine development efforts.

Research Archive Metric	Quantitative Data
Completed Clinical Trials	7 trials as of 2023
Ongoing Clinical Studies	3 active research programs
Research Data Volume	Over 500 terabytes of scientific data

Vaxart, Inc. (VXRT) - Business Model: Value Propositions

Innovative Oral Vaccine Technology Alternative to Injections

Vaxart's core value proposition centers on oral tablet vaccine technology. As of Q4 2023, the company has developed oral vaccine candidates targeting multiple infectious diseases including COVID-19, norovirus, and seasonal influenza.

Vaccine Technology	Development Status	Potential Advantage
Oral Tablet COVID-19 Vaccine	Phase 2 clinical trials completed	Room temperature stability
Oral Norovirus Vaccine	Preclinical stage	Mucosal immune response

Potential for Easier Vaccine Distribution and Administration

Vaxart's oral vaccine platform offers significant logistical advantages over traditional injectable vaccines.

• No cold chain requirements
• Self-administered format
• Reduced healthcare worker involvement

Cost-Effective Vaccine Development Approach

As of 2023 financial reports, Vaxart's R&D expenses were approximately $45.3 million, demonstrating a focused investment in oral vaccine technology development.

Financial Metric	2023 Value
R&D Expenses	$45.3 million
Total Operating Expenses	$67.2 million

Potential Reduced Storage and Transportation Complexities

Key advantages of oral vaccine technology include:

• No refrigeration requirements
• Simplified shipping logistics
• Lower distribution costs

Broad Applicability Across Multiple Disease Targets

Vaxart's vaccine platform targets multiple infectious disease indications, including:

Disease Target	Development Stage
COVID-19	Phase 2
Norovirus	Preclinical
Seasonal Influenza	Preclinical

Vaxart, Inc. (VXRT) - Business Model: Customer Relationships

Direct Engagement with Pharmaceutical Research Community

As of Q4 2023, Vaxart maintained direct communication channels with approximately 157 pharmaceutical research institutions globally. Engagement metrics include:

Engagement Type	Number of Interactions
Research Partnership Discussions	42
Technical Consultation Meetings	87
Collaborative Research Proposals	28

Scientific Conference and Industry Event Participation

Vaxart participated in 12 major scientific conferences during 2023, including:

• American Society for Microbiology Conference
• World Vaccine Congress
• International Vaccine Development Symposium

Transparent Communication of Clinical Trial Progress

Clinical trial communication metrics for 2023:

Communication Channel	Frequency
Press Releases	17
Investor Webinars	6
Detailed Trial Updates	24

Investor Relations and Shareholder Communication

Investor relationship statistics for 2023:

• Total Institutional Investors: 127
• Quarterly Earnings Call Participants: 215
• Investor Presentation Events: 8

Academic and Research Network Collaboration

Collaborative research network details:

Collaboration Type	Number of Partnerships
University Research Partnerships	23
Government Research Collaborations	7
International Research Networks	14

Vaxart, Inc. (VXRT) - Business Model: Channels

Direct Scientific Publications

Vaxart published 6 peer-reviewed scientific publications in 2023, targeting immunology and vaccine development journals.

Publication Type	Number in 2023	Primary Focus Areas
Peer-Reviewed Journals	6	Oral Vaccine Technology
Conference Proceedings	4	Vaccine Immunogenicity

Biotechnology Industry Conferences

Vaxart participated in 12 major biotechnology conferences in 2023.

• AAAS Annual Meeting
• American Society for Microbiology Conference
• World Vaccine Congress

Investor Relations Platforms

Vaxart utilized multiple investor communication channels with quarterly earnings calls reaching 287 institutional investors.

Platform	Investor Engagement Metrics
Earnings Calls	287 Institutional Investors
Investor Presentations	8 Major Investor Conferences

Digital Communication and Press Releases

Vaxart distributed 24 press releases in 2023, with digital reach extending to 156,000 professional contacts.

Regulatory Submission Channels

Submitted 3 regulatory packages to FDA in 2023 for oral vaccine technologies.

Regulatory Agency	Submission Type	Number of Submissions
FDA	Investigational New Drug (IND)	3
EMA	Clinical Trial Application	1

Vaxart, Inc. (VXRT) - Business Model: Customer Segments

Pharmaceutical Research Organizations

Vaxart targets pharmaceutical research organizations with its oral vaccine platform technology.

Segment Characteristics	Potential Market Size
Global pharmaceutical R&D spending	$186 billion in 2022
Number of active pharmaceutical research organizations	4,500 globally

Government Health Agencies

Vaxart focuses on government health agencies for vaccine development and distribution.

• Centers for Disease Control and Prevention (CDC) budget
• National Institutes of Health (NIH) vaccine research funding
• Global vaccine procurement programs

Agency	Annual Vaccine-Related Budget
CDC	$8.1 billion in 2022
NIH	$41.7 billion total research funding

Academic Research Institutions

Vaxart collaborates with academic research institutions for innovative vaccine technologies.

Institution Type	Number of Institutions	Research Funding
Research Universities	1,200 in United States	$86.5 billion total research expenditure

Vaccine Development Companies

Vaxart targets vaccine development companies with its oral vaccine platform.

• Global vaccine market size: $59.2 billion in 2022
• Number of active vaccine development companies: 250 globally

Global Healthcare Providers

Vaxart aims to serve global healthcare providers with innovative vaccine solutions.

Healthcare Provider Category	Global Count
Hospitals	59,000 worldwide
Clinics	153,000 globally

Vaxart, Inc. (VXRT) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Vaxart reported total R&D expenses of $35.4 million.

Fiscal Year	R&D Expenses
2022	$40.1 million
2023	$35.4 million

Clinical Trial Funding

Vaxart allocated approximately $22.7 million for clinical trial expenses in 2023.

• COVID-19 oral vaccine clinical trials: $12.5 million
• Norovirus vaccine clinical development: $6.2 million
• Influenza vaccine clinical programs: $4 million

Intellectual Property Maintenance

Annual intellectual property maintenance costs for Vaxart were $1.8 million in 2023.

Personnel and Scientific Staff Compensation

Personnel Category	Annual Compensation
Executive Leadership	$4.2 million
Scientific Staff	$9.6 million
Research Personnel	$6.3 million

Laboratory and Technology Infrastructure

Total infrastructure and technology investment in 2023 was $5.6 million.

• Laboratory equipment: $3.2 million
• Technology platforms: $1.8 million
• Software and computational resources: $0.6 million

Vaxart, Inc. (VXRT) - Business Model: Revenue Streams

Potential Vaccine Licensing Agreements

As of Q4 2023, Vaxart reported potential licensing revenue opportunities for its oral vaccine platform. No specific licensing agreement revenue was disclosed in the financial statements.

Research Grants and Funding

Year	Grant Source	Amount
2023	DARPA	$5.4 million
2022	National Institutes of Health	$3.2 million

Collaborative Development Contracts

Vaxart reported collaborative development contracts with multiple pharmaceutical partners, though specific contract values were not publicly disclosed in 2023 financial reports.

Potential Future Vaccine Product Sales

• COVID-19 oral vaccine candidate
• Norovirus vaccine development
• Seasonal influenza vaccine platform

Intellectual Property Monetization

Vaxart's intellectual property portfolio includes 12 patent families as of 2023, with potential future monetization strategies.

Financial Metric	2023 Value
Total Revenue	$6.8 million
Research and Development Expenses	$45.3 million